Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

A securities class action against Alexion Pharmaceuticals Inc. was “related” to an SEC investigation and should have been ...

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...

The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Based on those promising results, Cumberland Pharmaceuticals became the first recipient of an FDA Office of Orphan Products Development clinical trial grant for DMD, funding the development of ...

Amgen’s famously voracious legal team is living up to its reputation once again, this time with a surprise challenge on the patents surrounding Alexion’s rare diseases blockbuster, Soliris.